Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Kristina Blegen; Sara E. Ortiz-Romero; Olivia Juarez; Julie Voeller

doi:10.1111/pde.15044

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Kristina Blegen
, Sara E. Ortiz-Romero
, Olivia Juarez
, Julie Voeller

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11-year-old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.

Original language	English (US)
Pages (from-to)	764-766
Number of pages	3
Journal	Pediatric dermatology
Volume	39
Issue number	5
DOIs	https://doi.org/10.1111/pde.15044
State	Published - Sep 1 2022
Externally published	Yes

Keywords

NF1
elephantiasis neuromatosa
neurofibromatosis
plexiform neurofibroma
selumetinib

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Dermatology

Access to Document

10.1111/pde.15044

Cite this

@article{8985e7cbe44046a1b34fd57caa6cccec,

title = "Clinical impact of selumetinib on pediatric elephantiasis neuromatosa",

abstract = "Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11-year-old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.",

keywords = "NF1, elephantiasis neuromatosa, neurofibromatosis, plexiform neurofibroma, selumetinib",

author = "Kristina Blegen and Ortiz-Romero, \{Sara E.\} and Olivia Juarez and Julie Voeller",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC.",

year = "2022",

month = sep,

day = "1",

doi = "10.1111/pde.15044",

language = "English (US)",

volume = "39",

pages = "764--766",

journal = "Pediatric dermatology",

issn = "0736-8046",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

AU - Blegen, Kristina

AU - Ortiz-Romero, Sara E.

AU - Juarez, Olivia

AU - Voeller, Julie

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11-year-old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.

AB - Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11-year-old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.

KW - NF1

KW - elephantiasis neuromatosa

KW - neurofibromatosis

KW - plexiform neurofibroma

KW - selumetinib

UR - https://www.scopus.com/pages/publications/85132428875

UR - https://www.scopus.com/pages/publications/85132428875#tab=citedBy

U2 - 10.1111/pde.15044

DO - 10.1111/pde.15044

M3 - Article

C2 - 35739628

AN - SCOPUS:85132428875

SN - 0736-8046

VL - 39

SP - 764

EP - 766

JO - Pediatric dermatology

JF - Pediatric dermatology

IS - 5

ER -

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this